{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:51:06Z","timestamp":1790059866847,"version":"4.0.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/ncpneuro0452","type":"journal-article","created":{"date-parts":[[2007,4,4]],"date-time":"2007-04-04T11:15:27Z","timestamp":1175685327000},"page":"198-211","source":"Crossref","is-referenced-by-count":92,"title":["From bench to bedside\u2014experimental rationale for immune-specific therapies in the inflamed peripheral nerve"],"prefix":"10.1038","volume":"3","author":[{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd C","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneuro0452_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/B978-0-7216-9491-7.50101-0","volume-title":"Peripheral Neuropathy","author":"JW Griffin","year":"2005","unstructured":"Griffin JW and Sheikh K (2005) The Guillain\u2013Barr\u00e9 syndromes. In Peripheral Neuropathy, vol 2, 2197\u20132220 (Eds Dyck PJ and Thomas PK) Philadelphia: Elsevier Saunders"},{"key":"BFncpneuro0452_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes RA and Cornblath DR (2005) Guillain\u2013Barr\u00e9 syndrome. Lancet 366: 1653\u20131666","journal-title":"Lancet"},{"key":"BFncpneuro0452_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/mus.20076","volume":"30","author":"BC Kieseier","year":"2004","unstructured":"Kieseier BC et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131\u2013156","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/B978-0-7216-9491-7.50030-2","volume-title":"Peripheral Neuropathy","author":"R Gold","year":"2005","unstructured":"Gold R et al. (2005) Experimental autoimmune neuritis. In Peripheral Neuropathy, vol 1, 609\u2013634 (Eds Dyck PJ and Thomas PK) Philadelphia: Elsevier Saunders"},{"key":"BFncpneuro0452_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/00019052-200210000-00013","volume":"15","author":"M Maurer","year":"2002","unstructured":"Maurer M and Gold R (2002) Animal models of immune-mediated neuropathies. Curr Opin Neurol 15: 617\u2013622","journal-title":"Curr Opin Neurol"},{"key":"BFncpneuro0452_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-5728(00)00249-6","volume":"107","author":"DM Calida","year":"2000","unstructured":"Calida DM et al. (2000) Experimental allergic neuritis in the SJL\/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12. J Neuroimmunol 107: 1\u20137","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1189\/jlb.0604341","volume":"78","author":"X Chen","year":"2005","unstructured":"Chen X et al. (2005) BALB\/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25\u2212 responder T cells than C57BL\/6 mice. J Leukoc Biol 78: 114\u2013121","journal-title":"J Leukoc Biol"},{"key":"BFncpneuro0452_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2567.2005.02317.x","volume":"117","author":"C Dejaco","year":"2006","unstructured":"Dejaco C et al. (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117: 289\u2013300","journal-title":"Immunology"},{"key":"BFncpneuro0452_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/1097-4547(20001201)62:5<717::AID-JNR11>3.0.CO;2-P","volume":"62","author":"LP Zou","year":"2000","unstructured":"Zou LP et al. (2000) P0 protein peptide 180\u2013199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL\/6 mice. J Neurosci Res 62: 717\u2013721","journal-title":"J Neurosci Res"},{"key":"BFncpneuro0452_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jnen\/64.1.66","volume":"64","author":"H Miletic","year":"2005","unstructured":"Miletic H et al. (2005) P0(106\u2013125) is a neuritogenic epitope of the peripheral myelin protein P0 and induces autoimmune neuritis in C57BL\/6 mice. J Neuropathol Exp Neurol 64: 66\u201373","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFncpneuro0452_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho TW et al. (1995) Guillain\u2013Barr\u00e9 syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118: 597\u2013605","journal-title":"Brain"},{"key":"BFncpneuro0452_CR12","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison HJ and Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591\u20132625","journal-title":"Brain"},{"key":"BFncpneuro0452_CR13","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1212\/WNL.40.12.1900","volume":"40","author":"N Yuki","year":"1990","unstructured":"Yuki N et al. (1990) Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40: 1900\u20131902","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/jnr.10879","volume":"75","author":"S Jung","year":"2004","unstructured":"Jung S et al. (2004) Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 75: 524\u2013535","journal-title":"J Neurosci Res"},{"key":"BFncpneuro0452_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0022-510X(87)90097-9","volume":"81","author":"GK Harvey","year":"1987","unstructured":"Harvey GK et al. (1987) Chronic experimental allergic neuritis: an electrophysiological and histological study in the rabbit. J Neurol Sci 81: 215\u2013225","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1084\/jem.194.5.677","volume":"194","author":"B Salomon","year":"2001","unstructured":"Salomon B et al. (2001) Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 194: 677\u2013684","journal-title":"J Exp Med"},{"key":"BFncpneuro0452_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.coi.2005.09.004","volume":"17","author":"N Yuki","year":"2005","unstructured":"Yuki N (2005) Carbohydrate mimicry: a new paradigm of autoimmune diseases. Curr Opin Immunol 17: 577\u2013582","journal-title":"Curr Opin Immunol"},{"key":"BFncpneuro0452_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","volume":"10","author":"HJ Willison","year":"2005","unstructured":"Willison HJ (2005) The immunobiology of Guillain\u2013Barr\u00e9 syndromes. J Peripher Nerv Syst 10: 94\u2013112","journal-title":"J Peripher Nerv Syst"},{"key":"BFncpneuro0452_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0165-5728(93)90255-W","volume":"46","author":"A Khalili-Shirazi","year":"1993","unstructured":"Khalili-Shirazi A et al. (1993) Antibody responses to P0 and P2 myelin proteins in Guillain\u2013Barr\u00e9 syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 46: 245\u2013251","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archneur.1991.00530200100027","volume":"48","author":"FJ Vriesendorp","year":"1991","unstructured":"Vriesendorp FJ et al. (1991) Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain\u2013Barr\u00e9 syndrome treated and not treated with plasmapheresis. Arch Neurol 48: 858\u2013861","journal-title":"Arch Neurol"},{"key":"BFncpneuro0452_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-2990.2002.00421.x","volume":"28","author":"RD Hadden","year":"2002","unstructured":"Hadden RD et al. (2002) Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol 28: 489\u2013497","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFncpneuro0452_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1212\/01.WNL.0000041494.70178.17","volume":"60","author":"T Kanda","year":"2003","unstructured":"Kanda T et al. (2003) Sera from Guillain\u2013Barr\u00e9 patients enhance leakage in blood-nerve barrier model. Neurology 60: 301\u2013306","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/brain\/awh231","volume":"127","author":"SK Halstead","year":"2004","unstructured":"Halstead SK et al. (2004) Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127: 2109\u20132123","journal-title":"Brain"},{"key":"BFncpneuro0452_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awh127","volume":"127","author":"G Zhang","year":"2004","unstructured":"Zhang G et al. (2004) Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 127: 1085\u20131100","journal-title":"Brain"},{"key":"BFncpneuro0452_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0165-5728(03)00156-5","volume":"139","author":"A Dilley","year":"2003","unstructured":"Dilley A et al. (2003) Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain\u2013Barr\u00e9 syndrome. J Neuroimmunol 139: 133\u2013140","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1212\/WNL.56.1.67","volume":"56","author":"B Buchwald","year":"2001","unstructured":"Buchwald B et al. (2001) Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56: 67\u201374","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.37.6.1006","volume":"37","author":"HP Hartung","year":"1987","unstructured":"Hartung HP et al. (1987) Guillain\u2013Barr\u00e9 syndrome: activated complement components C3a and C5a in CSF. Neurology 37: 1006\u20131009","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/brain\/124.5.893","volume":"124","author":"GM O'Hanlon","year":"2001","unstructured":"O'Hanlon GM et al. (2001) Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124: 893\u2013906","journal-title":"Brain"},{"key":"BFncpneuro0452_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ana.410300205","volume":"30","author":"G Stoll","year":"1991","unstructured":"Stoll G et al. (1991) Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol 30: 147\u2013155","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","volume":"47","author":"WX Yan","year":"2000","unstructured":"Yan WX et al. (2000) Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 47: 765\u2013775","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/BF00294298","volume":"86","author":"AF Hahn","year":"1993","unstructured":"Hahn AF et al. (1993) Adoptive transfer of experimental allergic neuritis in the immune suppressed host. Acta Neuropathol (Berl) 86: 596\u2013601","journal-title":"Acta Neuropathol (Berl)"},{"key":"BFncpneuro0452_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1173","volume":"6","author":"M Krogsgaard","year":"2005","unstructured":"Krogsgaard M and Davis MM (2005) How T cells 'see' antigen. Nat Immunol 6: 239\u2013245","journal-title":"Nat Immunol"},{"key":"BFncpneuro0452_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nri1631","volume":"5","author":"G De Libero","year":"2005","unstructured":"De Libero G and Mori L (2005) Recognition of lipid antigens by T cells. Nat Rev Immunol 5: 485\u2013496","journal-title":"Nat Rev Immunol"},{"key":"BFncpneuro0452_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jocn.2004.04.006","volume":"12","author":"PA Csurhes","year":"2005","unstructured":"Csurhes PA et al. (2005) Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain\u2013Barr\u00e9 syndrome. J Clin Neurosci 12: 409\u2013415","journal-title":"J Clin Neurosci"},{"key":"BFncpneuro0452_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1212\/WNL.40.2.215","volume":"40","author":"HP Hartung","year":"1990","unstructured":"Hartung HP et al. (1990) T cell activation in Guillain\u2013Barr\u00e9 syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 40: 215\u2013218","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/brain\/awf070","volume":"125","author":"BC Kieseier","year":"2002","unstructured":"Kieseier BC et al. (2002) Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 125: 823\u2013834","journal-title":"Brain"},{"key":"BFncpneuro0452_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jneuroim.2005.07.019","volume":"168","author":"F Nicoletti","year":"2005","unstructured":"Nicoletti F et al. (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain\u2013Barr\u00e9 syndrome and experimental allergic neuritis. J Neuroimmunol 168: 168\u2013174","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/jnnp.69.3.362","volume":"69","author":"R Kiefer","year":"2000","unstructured":"Kiefer R et al. (2000) Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry 69: 362\u2013368","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1126\/science.272.5258.60","volume":"272","author":"EC Butcher","year":"1996","unstructured":"Butcher EC and Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272: 60\u201366","journal-title":"Science"},{"key":"BFncpneuro0452_CR40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/brain\/121.7.1257","volume":"121","author":"U Enders","year":"1998","unstructured":"Enders U et al. (1998) The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain 121: 1257\u20131266","journal-title":"Brain"},{"key":"BFncpneuro0452_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(98)00154-3","volume":"159","author":"JJ Archelos","year":"1998","unstructured":"Archelos JJ et al. (1998) Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J Neurol Sci 159: 127\u2013134","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0301-0082(00)00045-9","volume":"64","author":"SC Previtali","year":"2001","unstructured":"Previtali SC et al. (2001) Role of integrins in the peripheral nervous system. Prog Neurobiol 64: 35\u201349","journal-title":"Prog Neurobiol"},{"key":"BFncpneuro0452_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.410430404","volume":"43","author":"BC Kieseier","year":"1998","unstructured":"Kieseier BC et al. (1998) Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 43: 427\u2013434","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/121.3.481","volume":"121","author":"PM Hughes","year":"1998","unstructured":"Hughes PM et al. (1998) Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 121: 481\u2013494","journal-title":"Brain"},{"key":"BFncpneuro0452_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","volume":"39","author":"CE Hafer-Macko","year":"1996","unstructured":"Hafer-Macko CE et al. (1996) Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39: 625\u2013635","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410390105","volume":"39","author":"JW Griffin","year":"1996","unstructured":"Griffin JW et al. (1996) Pathology of the motor-sensory axonal Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 39: 17\u201328","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/0022-510X(93)90105-8","volume":"118","author":"B Bonetti","year":"1993","unstructured":"Bonetti B et al. (1993) Human peripheral nerve macrophages in normal and pathological conditions. J Neurol Sci 118: 158\u2013168","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR48","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1212\/01.WNL.0000098884.75756.4D","volume":"61","author":"W Hu","year":"2003","unstructured":"Hu W et al. (2003) Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 61: 1774\u20131779","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR49","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/brain\/118.4.869","volume":"118","author":"EJ Redford","year":"1995","unstructured":"Redford EJ et al. (1995) Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 118: 869\u2013878","journal-title":"Brain"},{"key":"BFncpneuro0452_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0166-2236(97)01079-5","volume":"20","author":"R Gold","year":"1997","unstructured":"Gold R et al. (1997) T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 20: 399\u2013404","journal-title":"Trends Neurosci"},{"key":"BFncpneuro0452_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00005072-199805000-00002","volume":"57","author":"R Kiefer","year":"1998","unstructured":"Kiefer R et al. (1998) Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. J Neuropathol Exp Neurol 57: 385\u2013395","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFncpneuro0452_CR52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jnnp.64.2.162","volume":"64","author":"A Cr\u00e9ange","year":"1998","unstructured":"Cr\u00e9ange A et al. (1998) Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain\u2013Barr\u00e9 syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 64: 162\u2013165","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR53","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.4049\/jimmunol.147.7.2155","volume":"147","author":"CC Whitacre","year":"1991","unstructured":"Whitacre CC et al. (1991) Oral tolerance in experimental autoimmune encephalomyelitis. III: evidence for clonal anergy. J Immunol 147: 2155\u20132163","journal-title":"J Immunol"},{"key":"BFncpneuro0452_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/376177a0","volume":"376","author":"Y Chen","year":"1995","unstructured":"Chen Y et al. (1995) Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376: 177\u2013180","journal-title":"Nature"},{"key":"BFncpneuro0452_CR55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7520605","volume":"265","author":"Y Chen","year":"1994","unstructured":"Chen Y et al. (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237\u20131240","journal-title":"Science"},{"key":"BFncpneuro0452_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ana.410380214","volume":"38","author":"I Illa","year":"1995","unstructured":"Illa I et al. (1995) Acute axonal Guillain\u2013Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 38: 218\u2013224","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00415-005-0805-0","volume":"252","author":"E Nobile-Orazio","year":"2005","unstructured":"Nobile-Orazio E (2005) Treatment of dys-immune neuropathies. J Neurol 252: 385\u2013395","journal-title":"J Neurol"},{"key":"BFncpneuro0452_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0022-510X(83)90001-1","volume":"61","author":"ML Gross","year":"1983","unstructured":"Gross ML et al. (1983) The treatment of experimental allergic neuritis by plasma exchange. J Neurol Sci 61: 149\u2013160","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/jnnp.52.7.865","volume":"52","author":"GK Harvey","year":"1989","unstructured":"Harvey GK et al. (1989) IgG immunoadsorption in experimental allergic neuritis: effect on antibody levels and clinical course. J Neurol Neurosurg Psychiatry 52: 865\u2013870","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR60","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/brain\/120.9.1533","volume":"120","author":"CM Gabriel","year":"1997","unstructured":"Gabriel CM et al. (1997) Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120: 1533\u20131540","journal-title":"Brain"},{"key":"BFncpneuro0452_CR61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0165-5728(97)00090-8","volume":"78","author":"F Miyagi","year":"1997","unstructured":"Miyagi F et al. (1997) Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 78: 127\u2013131","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR62","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/brain\/124.9.1791","volume":"124","author":"T Korn","year":"2001","unstructured":"Korn T et al. (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124: 1791\u20131802","journal-title":"Brain"},{"key":"BFncpneuro0452_CR63","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"H Koller","year":"2005","unstructured":"Koller H et al. (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352: 1343\u20131356","journal-title":"N Engl J Med"},{"key":"BFncpneuro0452_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0165-5728(97)00238-5","volume":"84","author":"J Zhu","year":"1998","unstructured":"Zhu J et al. (1998) Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain\u2013Barr\u00e9 syndrome. J Neuroimmunol 84: 40\u201352","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0923-2494(92)80040-R","volume":"143","author":"G Said","year":"1992","unstructured":"Said G and Hontebeyrie-Joskowicz M (1992) Nerve lesions induced by macrophage activation. Res Immunol 143: 589\u2013599","journal-title":"Res Immunol"},{"key":"BFncpneuro0452_CR66","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1006\/exnr.2001.7662","volume":"169","author":"Y Zhu","year":"2001","unstructured":"Zhu Y et al. (2001) Suppression of autoimmune neuritis in IFN-\u03b3 receptor-deficient mice. Exp Neurol 169: 472\u2013478","journal-title":"Exp Neurol"},{"key":"BFncpneuro0452_CR67","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/brain\/120.10.1895","volume":"120","author":"EJ Redford","year":"1997","unstructured":"Redford EJ et al. (1997) A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-\u03b1 processing attenuates experimental autoimmune neuritis. Brain 120: 1895\u20131905","journal-title":"Brain"},{"key":"BFncpneuro0452_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0301-0082(00)00060-5","volume":"64","author":"R Kiefer","year":"2001","unstructured":"Kiefer R et al. (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109\u2013127","journal-title":"Prog Neurobiol"},{"key":"BFncpneuro0452_CR69","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/B978-0-7216-9491-7.50031-4","volume-title":"Peripheral Neuropathy","author":"JD Pollard","year":"2005","unstructured":"Pollard JD et al. (2005) Principles of immunotherapy. In Peripheral Neuropathy, vol 1, 635\u2013648 (Eds Dyck PJ and Thomas PK) Philadelphia: Elsevier Saunders"},{"key":"BFncpneuro0452_CR70","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/01.wco.0000175937.31569.15","volume":"18","author":"JM Leger","year":"2005","unstructured":"Leger JM and Behin A (2005) Multifocal motor neuropathy. Curr Opin Neurol 18: 567\u2013573","journal-title":"Curr Opin Neurol"},{"key":"BFncpneuro0452_CR71","doi-asserted-by":"crossref","unstructured":"Umapathi T et al. Immunosuppressant and immunomodulatory treatment for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003217.pub2. DOI: 10.1002\/14651858.CD003217.pub2","DOI":"10.1002\/14651858.CD003217.pub2"},{"key":"BFncpneuro0452_CR72","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/01.wco.0000175479.03969.13","volume":"18","author":"RA Hughes","year":"2005","unstructured":"Hughes RA (2005) Treatment of peripheral nerve disorders. Curr Opin Neurol 18: 554\u2013556","journal-title":"Curr Opin Neurol"},{"key":"BFncpneuro0452_CR73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ncpneuro0376","volume":"3","author":"R Gold","year":"2007","unstructured":"Gold R et al. (2007) Drug insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues. Nat Clin Pract Neurol 3: 36\u201344","journal-title":"Nat Clin Pract Neurol"},{"key":"BFncpneuro0452_CR74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archneur.63.7.930","volume":"63","author":"HC Lehmann","year":"2006","unstructured":"Lehmann HC et al. (2006) Plasma exchange in neuroimmunological disorders. Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63: 930\u2013935","journal-title":"Arch Neurol"},{"key":"BFncpneuro0452_CR75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R van Koningsveld","year":"2004","unstructured":"van Koningsveld R et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial. Lancet 363: 192\u2013196","journal-title":"Lancet"},{"key":"BFncpneuro0452_CR76","volume-title":"Cochrane Database of Systematic Reviews","author":"MM Mehndiratta","year":"2002","unstructured":"Mehndiratta MM and Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD002062. DOI: 10.1002\/14651858.CD002062"},{"key":"BFncpneuro0452_CR77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archneur.62.2.249","volume":"62","author":"G Lopate","year":"2005","unstructured":"Lopate G et al. (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62: 249\u2013254","journal-title":"Arch Neurol"},{"key":"BFncpneuro0452_CR78","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00415-002-0693-5","volume":"249","author":"G Pavesi","year":"2002","unstructured":"Pavesi G et al. (2002) Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 249: 777\u2013779","journal-title":"J Neurol"},{"key":"BFncpneuro0452_CR79","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.50.1.84","volume":"50","author":"KC Gorson","year":"1998","unstructured":"Gorson KC et al. (1998) Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 50: 84\u201387","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O","volume":"23","author":"MN Meriggioli","year":"2000","unstructured":"Meriggioli MN and Rowin J (2000) Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-\u03b1. Muscle Nerve 23: 433\u2013435","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR81","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0140-6736(05)60466-7","volume":"352","author":"A Creange","year":"1998","unstructured":"Creange A et al. (1998) Treatment of Guillain\u2013Barr\u00e9 syndrome with interferon-\u03b2. Lancet 352: 368\u2013369","journal-title":"Lancet"},{"key":"BFncpneuro0452_CR82","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","volume":"61","author":"J Pritchard","year":"2003","unstructured":"Pritchard J et al. (2003) A randomized controlled trial of recombinant interferon-beta 1a in Guillain\u2013Barr\u00e9 syndrome. Neurology 61: 1282\u20131284","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-510X(03)00010-8","volume":"210","author":"RL Chin","year":"2003","unstructured":"Chin RL et al. (2003) Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 210: 19\u201321","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR84","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1085-9489.2005.00053.x","volume":"10","author":"D Cocito","year":"2005","unstructured":"Cocito D et al. (2005) Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 10: 386\u2013387","journal-title":"J Peripher Nerv Syst"},{"key":"BFncpneuro0452_CR85","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","volume":"35","author":"PJ Dyck","year":"1985","unstructured":"Dyck PJ et al. (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35: 1173\u20131176","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR86","volume-title":"Cochrane Database of Systematic Reviews","author":"RAC Hughes","year":"2004","unstructured":"Hughes RAC et al. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD003280.pub2. DOI: 10.1002\/14651858.CD003280.pub2"},{"key":"BFncpneuro0452_CR87","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jnnp.2005.074781","volume":"77","author":"D Fialho","year":"2006","unstructured":"Fialho D et al. (2006) Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 77: 544\u2013547","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/jnnp.60.2.185","volume":"60","author":"W Mahattanakul","year":"1996","unstructured":"Mahattanakul W et al. (1996) Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 60: 185\u2013187","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jns.2004.05.014","volume":"224","author":"M Matsuda","year":"2004","unstructured":"Matsuda M et al. (2004) Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 224: 29\u201335","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR90","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.pediatrneurol.2005.05.015","volume":"33","author":"A Visudtibhan","year":"2005","unstructured":"Visudtibhan A et al. (2005) Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 33: 368\u2013372","journal-title":"Pediatr Neurol"},{"key":"BFncpneuro0452_CR91","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1212\/01.WNL.0000134676.05850.C0","volume":"63","author":"KC Gorson","year":"2004","unstructured":"Gorson KC et al. (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63: 715\u2013717","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1085-9489.2005.10104.x","volume":"10","author":"DE Gladstone","year":"2005","unstructured":"Gladstone DE et al. (2005) High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 10: 11\u201316","journal-title":"J Peripher Nerv Syst"},{"key":"BFncpneuro0452_CR93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"S Renaud","year":"2003","unstructured":"Renaud S et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611\u2013615","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR94","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","volume":"66","author":"S Renaud","year":"2006","unstructured":"Renaud S et al. (2006) High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 66: 742\u2013744","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR95","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jocn.2005.09.008","volume":"13","author":"T Gono","year":"2006","unstructured":"Gono T et al. (2006) Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 13: 683\u2013687","journal-title":"J Clin Neurosci"},{"key":"BFncpneuro0452_CR96","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","volume":"63","author":"SJ Ruegg","year":"2004","unstructured":"Ruegg SJ et al. (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63: 2178\u20132179","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR97","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/mus.20386","volume":"32","author":"L Broglio","year":"2005","unstructured":"Broglio L and Lauria G (2005) Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 32: 378\u2013379","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR98","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5: 564\u2013576","journal-title":"Nat Rev Drug Discov"},{"key":"BFncpneuro0452_CR99","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jnnp.2005.076869","volume":"77","author":"C Hirst","year":"2006","unstructured":"Hirst C et al. (2006) Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 77: 800\u2013802","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR100","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1704538","volume":"34","author":"I Avivi","year":"2004","unstructured":"Avivi I et al. (2004) Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 34: 137\u2013142","journal-title":"Bone Marrow Transplant"},{"key":"BFncpneuro0452_CR101","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/mus.880170510","volume":"17","author":"JR Wilson","year":"1994","unstructured":"Wilson JR et al. (1994) Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 17: 528\u2013532","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR102","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1006\/jaut.1998.0259","volume":"12","author":"G Deretzi","year":"1999","unstructured":"Deretzi G et al. (1999) Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination. J Autoimmun 12: 81\u201389","journal-title":"J Autoimmun"},{"key":"BFncpneuro0452_CR103","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/(SICI)1097-4598(199912)22:12<1704::AID-MUS13>3.0.CO;2-A","volume":"22","author":"K Miyamoto","year":"1999","unstructured":"Miyamoto K et al. (1999) The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis. Muscle Nerve 22: 1704\u20131709","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0452_CR104","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08916930008994078","volume":"32","author":"N Abbas","year":"2000","unstructured":"Abbas N et al. (2000) Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 32: 93\u201399","journal-title":"Autoimmunity"},{"key":"BFncpneuro0452_CR105","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/brain\/121.10.1895","volume":"121","author":"CM Gabriel","year":"1998","unstructured":"Gabriel CM et al. (1998) Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 121: 1895\u20131902","journal-title":"Brain"},{"key":"BFncpneuro0452_CR106","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0165-5728(99)00047-8","volume":"97","author":"PA McCombe","year":"1999","unstructured":"McCombe PA et al. (1999) Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J Neuroimmunol 97: 60\u201369","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR107","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0006-8993(80)90071-2","volume":"195","author":"PM Hoffman","year":"1980","unstructured":"Hoffman PM et al. (1980) Experimental allergic neuritis. I: rat strain differences in the response to bovine myelin antigens. Brain Res 195: 355\u2013362","journal-title":"Brain Res"},{"key":"BFncpneuro0452_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/brain\/114.1.429","volume":"114","author":"H Lassmann","year":"1991","unstructured":"Lassmann H et al. (1991) Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines. Brain 114: 429\u2013442","journal-title":"Brain"},{"key":"BFncpneuro0452_CR109","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0165-5728(85)80055-2","volume":"8","author":"WA Taylor","year":"1985","unstructured":"Taylor WA and Hughes RA (1985) Experimental allergic neuritis induced in SJL mice by bovine P2. J Neuroimmunol 8: 153\u2013157","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR110","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1084\/jem.182.2.587","volume":"182","author":"S Abromson-Leeman","year":"1995","unstructured":"Abromson-Leeman S et al. (1995) Experimental autoimmune peripheral neuritis induced in BALB\/c mice by myelin basic protein-specific T cell clones. J Exp Med 182: 587\u2013592","journal-title":"J Exp Med"},{"key":"BFncpneuro0452_CR111","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0022-510X(80)90198-7","volume":"48","author":"M Kadlubowski","year":"1980","unstructured":"Kadlubowski M and Hughes RA (1980) The neuritogenicity and encephalitogenicity of P2 in the rat, guinea-pig and rabbit. J Neurol Sci 48: 171\u2013178","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0452_CR112","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/jnnp.49.3.258","volume":"49","author":"G Stoll","year":"1986","unstructured":"Stoll G et al. (1986) Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis. J Neurol Neurosurg Psychiatry 49: 258\u2013264","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR113","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.1012","volume":"49","author":"N Yuki","year":"2001","unstructured":"Yuki N et al. (2001) Animal model of axonal Guillain\u2013Barr\u00e9 syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49: 712\u2013720","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR114","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.410390404","volume":"39","author":"S Kusunoki","year":"1996","unstructured":"Kusunoki S et al. (1996) Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39: 424\u2013431","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR115","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/00005072-197705000-00007","volume":"36","author":"DH Snyder","year":"1977","unstructured":"Snyder DH et al. (1977) Attempts to induce chronic experimental allergic neuritis in strain 13 and Hartley guinea pigs. J Neuropathol Exp Neurol 36: 488\u2013498","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFncpneuro0452_CR116","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0165-5728(82)90043-1","volume":"3","author":"EH Eylar","year":"1982","unstructured":"Eylar EH et al. (1982) Induction of allergic neuritis in rhesus monkeys. J Neuroimmunol 3: 91\u201398","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0452_CR117","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1212\/WNL.46.1.100","volume":"46","author":"V Bril","year":"1996","unstructured":"Bril V et al. (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain\u2013Barr\u00e9 syndrome. Neurology 46: 100\u2013103","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR118","doi-asserted-by":"crossref","unstructured":"French et al. (1987) Efficacy of plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 22: 753\u2013761","DOI":"10.1002\/ana.410220612"},{"key":"BFncpneuro0452_CR119","volume-title":"Cochrane Database of Systematic Reviews","author":"JC Raphael","year":"2001","unstructured":"Raphael JC et al. Plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD001798. DOI: 10.1002\/14651858.CD001798"},{"key":"BFncpneuro0452_CR120","doi-asserted-by":"crossref","unstructured":"The et al. (1997) Appropriate number of plasma exchanges in Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 41: 298\u2013306","DOI":"10.1002\/ana.410410304"},{"key":"BFncpneuro0452_CR121","doi-asserted-by":"crossref","unstructured":"The et al. (1985) Plasmapheresis and acute Guillain\u2013Barr\u00e9 syndrome. Neurology 35: 1096\u20131104","DOI":"10.1212\/WNL.35.8.1096"},{"key":"BFncpneuro0452_CR122","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1212\/WNL.43.12.2730","volume":"43","author":"FG van der Mech\u00e9","year":"1993","unstructured":"van der Mech\u00e9 FG et al. (1993) Intravenous immunoglobulin versus plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Neurology 43: 2730","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR123","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM198602203140801","volume":"314","author":"PJ Dyck","year":"1986","unstructured":"Dyck PJ et al. (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461\u2013465","journal-title":"N Engl J Med"},{"key":"BFncpneuro0452_CR124","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF et al. (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 119: 1055\u20131066","journal-title":"Brain"},{"key":"BFncpneuro0452_CR125","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"JC Raphael","year":"2001","unstructured":"Raphael JC et al. (2001) Intravenous immune globulins in patients with Guillain\u2013Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235\u2013238","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR126","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.410300119","volume":"30","author":"DR Cornblath","year":"1991","unstructured":"Cornblath DR et al. (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 30: 104\u2013106","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR127","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF et al. (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 119: 1067\u20131077","journal-title":"Brain"},{"key":"BFncpneuro0452_CR128","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"JR Mendell","year":"2001","unstructured":"Mendell JR et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demeylinating polyradiculoneuropathy. Neurology 56: 445\u2013449","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR129","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1212\/WNL.40.2.209","volume":"40","author":"P van Doorn","year":"1990","unstructured":"van Doorn P et al. (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40: 209\u2013212","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR130","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"P Federico","year":"2000","unstructured":"Federico P et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256\u20131262","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR131","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1212\/WNL.55.9.1246","volume":"55","author":"PA van Doorn","year":"2000","unstructured":"van Doorn PA and van der Mech\u00e9 FG (2000) IVIg treatment improves multifocal motor neuropathy: easy to start but difficult to stop. Neurology 55: 1246\u20131247","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR132","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"JM Leger","year":"2001","unstructured":"Leger JM et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145\u2013153","journal-title":"Brain"},{"key":"BFncpneuro0452_CR133","volume-title":"Cochrane Database of Systematic Reviews","author":"RAC Hughes","year":"2000","unstructured":"Hughes RAC and van der Mech\u00e9 FG. Corticosteroids for Guillain\u2013Barr\u00e9 syndrome (Archive). Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001446. DOI: 10.1002\/14651858.CD001446"},{"key":"BFncpneuro0452_CR134","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculopathy. Ann Neurol 50: 195\u2013201","journal-title":"Ann Neurol"},{"key":"BFncpneuro0452_CR135","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.48.3.777","volume":"48","author":"KC Gorson","year":"1997","unstructured":"Gorson KC et al. (1997) Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 48: 777\u2013780","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR136","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000050798","volume":"46","author":"B Schaller","year":"2001","unstructured":"Schaller B et al. (2001) Successful treatment of Guillain\u2013Barr\u00e9 syndrome with combined administration of interferon-\u03b21a and intravenous immunoglobulin. Eur Neurol 46: 167\u2013168","journal-title":"Eur Neurol"},{"key":"BFncpneuro0452_CR137","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/jnnp.66.2.197","volume":"66","author":"IS Martina","year":"1999","unstructured":"Martina IS et al. (1999) Chronic motor neuropathies: response to interferon-\u03b21a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 66: 197\u2013201","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR138","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.53.1.57","volume":"53","author":"R Hadden","year":"1999","unstructured":"Hadden R et al. (1999) Randomized trial of interferon \u03b2-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53: 57\u201361","journal-title":"Neurology"},{"key":"BFncpneuro0452_CR139","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/jnnp.53.4.327","volume":"53","author":"SJ Hodgkinson","year":"1990","unstructured":"Hodgkinson SJ et al. (1990) Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53: 327\u2013330","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0452_CR140","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1046\/j.1468-1331.2002.00478.x","volume":"9","author":"T Umapathi","year":"2002","unstructured":"Umapathi T and Hughes R (2002) Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 9: 683\u2013685","journal-title":"Eur J Neurol"},{"key":"BFncpneuro0452_CR141","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410240113","volume":"24","author":"A Pestronk","year":"1988","unstructured":"Pestronk A et al. (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24: 73\u201378","journal-title":"Ann Neurol"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0452","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpneuro0452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T16:29:06Z","timestamp":1684427346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BFncpneuro0452"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0452","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1084884.538708","asserted-by":"object"}]},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}